Phase 2 Stomach Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 75 years, of any gender.
• People who have been diagnosed with stomach (gastric) cancer or cancer at the junction of the stomach and food pipe (gastroesophageal junction), confirmed through tissue testing.
• People whose cancer cannot be removed by surgery and has either spread to nearby areas or to other parts of the body, where the tumour sites are suitable for radiation treatment — but not those with cancer that has spread to the brain or spread very widely throughout the body.
• People whose cancer tests negative for a protein called HER2.
• People who are generally well enough to carry out everyday activities with little or no limitation (this is measured on a standard scale called ECOG, and a score of 0 or 1 is required).
• People who have at least one tumour that can be measured on scans, using standard measurement guidelines.
• People whose blood, kidney, and liver results fall within acceptable ranges — including healthy levels of red blood cells, white blood cells, platelets, kidney markers, liver enzymes, and normal blood clotting (confirm specific values with the trial site).
• People who have no medical reasons that would prevent them from receiving immunotherapy.
• People who have no known allergies to a class of chemotherapy drugs called fluoropyrimidines or platinum-based agents.
• People who have not previously received surgery, chemotherapy, immunotherapy, or any other cancer treatment for their stomach or gastroesophageal junction cancer.
• People who have not previously had radiation treatment to the areas being targeted in this trial.
• People who are willing and able to understand the study and sign a consent form.

Who may not be able to join:

• People whose cancer has spread to the brain or has spread very extensively throughout the body.
• People who have previously been treated with certain types of immunotherapy drugs (including PD-1, PD-L1, TGF-β, or CTLA-4 inhibitors, or other experimental immunotherapy treatments).
• People who have a serious autoimmune condition, such as inflammatory bowel disease (Crohn's disease or ulcerative colitis), rheumatoid arthritis, scleroderma, lupus, or autoimmune blood vessel inflammation.
• People who have active lung inflammation or scarring (interstitial lung disease or pneumonitis) causing symptoms.
• People who have conditions that raise the risk of a hole forming in the gut, such as active diverticulitis, an abscess in the abdomen, a blockage in the bowel, or cancer spread across the lining of the abdomen.
• People with a history of another cancer, except for certain early-stage skin cancers or a specific type of early cervical cancer that has been fully treated (confirm with trial site).
• People who have an active serious infection, heart failure, a heart attack in the past six months, unstable chest pain, or an unstable irregular heartbeat.
• People whose test results or health conditions, in the doctor's judgement, could interfere with the trial or make treatment more risky.
• People who are pregnant or breastfeeding.
• People with a weakened immune system due to a condition present from birth, HIV infection, or a history of organ transplant or bone marrow transplant.
• People with active hepatitis B (above a specific level in the blood), active hepatitis C, or active tuberculosis.
• People who have received a live vaccine within four weeks before starting the study treatment (certain inactivated flu vaccines may be acceptable — confirm with trial site).
• People currently receiving immunosuppressive medications, chemotherapy, other experimental drugs, or ongoing high-dose steroid treatment.
• People with psychiatric conditions, substance use issues, or personal circumstances that the doctor believes could affect their ability to follow the treatment plan.
• People with a known allergy or medical reason to avoid any of the treatments used in this trial.

Important: Always verify eligibility with the trial site directly before applying.